Looking for Earnings Beat? Buy These 5 Top-Ranked Stocks
Top-ranked stocks Urban Outfitters (URBN), Tenet Healthcare (THC), Five9 (FIVN), Marqeta (MQ) and Exelixis (EXEL) are likely to beat on the bottom line in their upcoming releases.
Why Exelixis (EXEL) is a Top Value Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Exelixis (EXEL) Upgraded to Buy: What Does It Mean for the Stock?
Exelixis (EXEL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Earnings Estimates Moving Higher for Exelixis (EXEL): Time to Buy?
Exelixis (EXEL) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
3 Reasons Why Growth Investors Shouldn't Overlook Exelixis (EXEL)
Exelixis (EXEL) possesses solid growth attributes, which could help it handily outperform the market.
EXEL vs. ARGX: Which Stock Is the Better Value Option?
Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Exelixis (EXEL) and argenex SE (ARGX). But which of these two stocks offers value investors a better bang for their buck right now?
EXEL Reports Superior Efficacy Data From Kidney Cancer Study Cohort
Exelixis' zanzalintinib/Opdivo combo shows superior efficacy for treating kidney cancer in an expansion cohort of the phase Ib/II STELLAR-002 study.
Product Performance, Big Money Lift Exelixis
Shares of Exelixis, Inc. (EXEL), an oncology-focused biopharmaceutical firm, boosted by Big Money inflows.
Exelixis (EXEL) is a Great Momentum Stock: Should You Buy?
Does Exelixis (EXEL) have what it takes to be a top stock pick for momentum investors? Let's find out.
Unlocking Exelixis (EXEL) International Revenues: Trends, Surprises, and Prospects
Explore Exelixis' (EXEL) international revenue trends and how these numbers impact Wall Street's forecasts and what's ahead for the stock.
Why Exelixis (EXEL) is a Top Growth Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Exelixis: A Notable Quarter
Exelixis just delivered a strong Q1 beat, raised 2025 guidance, and continues to benefit from robust Cabometyx sales and share buybacks. The company is transitioning to zanzalintinib as its next flagship drug, but pivotal trial success remains uncertain, and skepticism persists among analysts. The company has a rock-solid balance sheet with some $1.75 billion in cash and no long-term debt.
